Director at Crescent Biopharma (CBIO) receives option grant for 11,050 shares

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. director Susan Moran received a grant of options to buy 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to her continued service, leaving her with 11,050 derivative securities directly held after this transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Moran Susan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	11,050	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 11,050 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 11,050 options Exercise price: $17.01 per share Expiration date: June 2, 2036 +3 more

6 metrics

Option grant size 11,050 options Stock Option (Right to Buy) granted to director Susan Moran

Exercise price $17.01 per share Conversion or exercise price for the stock options

Expiration date June 2, 2036 Option expiration date for the grant

Underlying shares 11,050 ordinary shares Shares underlying the stock option grant

Post-transaction derivative holdings 11,050 derivative securities Total options held directly after this transaction

Vesting trigger date June 2, 2027 or next annual meeting Earlier date determines full vesting, subject to continued service

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Ordinary Shares, derivative securities

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

derivative securities financial

"derivativeTransactionCount for derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Susan

(Last) (First) (Middle)

C/O/ CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17.01	06/02/2026		A		11,050		(1)	06/02/2036	Ordinary Shares	11,050	$0	11,050	D

Explanation of Responses:

1. This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Barbara Bispham, as attorney-in-fact for Susan Moran	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Crescent Biopharma (CBIO) report for Susan Moran?

Crescent Biopharma reported that director Susan Moran received a stock option grant for 11,050 ordinary shares. The award is a compensation-related acquisition, not an open-market purchase or sale, and was recorded as a derivative security with a fixed exercise price and expiration date.

How many Crescent Biopharma (CBIO) shares are covered by Susan Moran’s new options?

Susan Moran’s option grant covers 11,050 of Crescent Biopharma’s ordinary shares. Each option represents the right to buy one share, giving her potential future ownership if she chooses to exercise the options once they are vested and before they expire.

What is the exercise price and expiration date of Susan Moran’s CBIO options?

The options granted to Susan Moran have an exercise price of $17.01 per Crescent Biopharma ordinary share and expire on June 2, 2036. She can only benefit from them by exercising at or before that expiration date once they are vested.

When do Susan Moran’s Crescent Biopharma (CBIO) options vest?

Susan Moran’s options vest in full on the earlier of June 2, 2027 or the date of Crescent Biopharma’s next annual shareholder meeting. Vesting is conditioned on her continued service to the company through that date, aligning the award with ongoing board involvement.

Did Susan Moran buy or sell Crescent Biopharma (CBIO) shares in the market?

The disclosed transaction is a grant of stock options, not a market buy or sell of Crescent Biopharma shares. It is coded as an acquisition (A) for compensation, giving her a right to purchase shares in the future rather than an immediate cash transaction.